1 Horton, R. et al. Gene map of the extended human MHC. Nat Rev Genet 5, 889-899, doi:10.1038/nrg1489 (2004).
2 Mizuki, N. et al. Nucleotide sequence analysis of the HLA class I region spanning the 237-kb segment around the HLA-B and -C genes. Genomics 42, 55-66, doi:10.1006/geno.1997.4708 (1997).
3 Li, P. et al. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2, 443-451, doi:10.1038/87757 (2001).
4 Groh, V. et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proceedings of the National Academy of Sciences 93, 12445-12450, doi:10.1073/pnas.93.22.12445 (1996).
5 Groh, V., Steinle, A., Bauer, S. & Spies, T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science (New York, N.Y.) 279, 1737-1740, doi:10.1126/science.279.5357.1737 (1998).
6 Groh, V. et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nature immunology 2, 255-260, doi:10.1038/85321 (2001).
7 Schreiner, B. et al. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20, 118-120, doi:10.1096/fj.05-4342fje (2006).
8 Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190, doi:10.1038/nature03884 (2005).
9 Tang, K. F. et al. Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB. The Journal of cell biology 182, 233-239, doi:10.1083/jcb.200801169 (2008).
10 Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738, doi:10.1038/nature01112 (2002).
11 Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proceedings of the National Academy of Sciences of the United States of America 96, 6879-6884, doi:10.1073/pnas.96.12.6879 (1999).
12 Terasaki, P. I. & McClelland, J. D. MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS. Nature 204, 998-1000, doi:10.1038/204998b0 (1964).
13 Terasaki, P. I. Humoral theory of transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 3, 665-673, doi:10.1034/j.1600-6143.2003.00135.x (2003).
14 Patel, R. & Terasaki, P. I. Significance of the Positive Crossmatch Test in Kidney Transplantation. New England Journal of Medicine 280, 735-739, doi:10.1056/nejm196904032801401 (1969).
15 Perrey, C., Brenchley, P. E., Johnson, R. W. & Martin, S. An association between antibodies specific for endothelial cells and renal transplant failure. Transplant immunology 6, 101-106, doi:10.1016/s0966-3274(98)80024-5 (1998).
16 Ball, B. et al. Antibodies to vascular endothelial cells in chronic rejection of renal allografts. Transplantation proceedings 32, 353-354, doi:10.1016/s0041-1345(99)00976-8 (2000).
17 Ferry, B. L. et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transplant immunology 5, 17-24, doi:10.1016/s0966-3274(97)80021-4 (1997).
18 Zwirner, N. W., Marcos, C. Y., Mirbaha, F., Zou, Y. & Stastny, P. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Human immunology 61, 917-924, doi:10.1016/s0198-8859(00)00162-2 (2000).
19 Williams, G. M. et al. Hyperacute Renal-Homograft Rejection in Man. New England Journal of Medicine 279, 611-618, doi:10.1056/nejm196809192791201 (1968).
20 Rebellato, L. M. et al. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development. Clinical transplants, 241-253 (2006).
21 El-Awar, N., Lee, J. & Terasaki, P. I. HLA antibody identification with single antigen beads compared to conventional methods. Human immunology 66, 989-997, doi:10.1016/j.humimm.2005.07.005 (2005).
22 Hancock, K. et al. False positive reactivity of recombinant, diagnostic, glycoproteins produced in High Five insect cells: effect of glycosylation. Journal of immunological methods 330, 130-136, doi:10.1016/j.jim.2007.08.002 (2008).
23 Hong, C. H., Sohn, H. J., Lee, H. J., Cho, H. I. & Kim, T. G. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System. Journal of immunotherapy (Hagerstown, Md. : 1997) 40, 201-210, doi:10.1097/cji.0000000000000176 (2017).
24 Mizutani, K. et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 5, 2265-2272, doi:10.1111/j.1600-6143.2005.01016.x (2005).
25 Zou, Y., Qin, Z., Silveus, A., Fan, Y. & Stastny, P. Polymorphisms of MICA recognized by human alloantibodies. Immunogenetics 61, 91-100, doi:10.1007/s00251-008-0344-9 (2009).
26 Zoet, Y. M. et al. Challenging the golden standard in defining donor-specific antibodies: does the solid phase assay meet the expectations? Tissue antigens 77, 225-228, doi:10.1111/j.1399-0039.2010.01608.x (2011).
27 Zou, Y. et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Human immunology 67, 230-237, doi:10.1016/j.humimm.2006.02.017 (2006).
28 Baek, I. C. et al. Microarrays for high-throughput genotyping of MICA alleles using allele-specific primer extension. Tissue Antigens 82, 259-268, doi:10.1111/tan.12201 (2013).
29 Min, J. W. et al. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients. 38, 450-457, doi:10.3343/alm.2018.38.5.450 (2018).
30 Lee, N. et al. Associations of Anti-MHC Class I-related Chain A (MICA) Antibodies with Renal Allograft Outcomes. Annals of clinical and laboratory science 50, 247-252 (2020).